Published in Nat Biotechnol on February 01, 1997
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Dual targeting strategies with bispecific antibodies. MAbs (2012) 2.13
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A (2011) 1.85
6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland. MAbs (2011) 1.61
Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjug Chem (2007) 1.36
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs (2009) 1.30
A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel (2009) 1.29
Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci U S A (2011) 1.15
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood (2009) 0.99
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem (2010) 0.97
Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol (2010) 0.97
Designed auto-assembly of nanostreptabodies for rapid tissue-specific targeting in vivo. J Biol Chem (2009) 0.95
Emerging antibody combinations in oncology. MAbs (2011) 0.94
Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs (2013) 0.93
Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood (2007) 0.93
Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models. BMC Biotechnol (2007) 0.92
Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother (2011) 0.90
Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs (2011) 0.90
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel (2012) 0.85
Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells. MAbs (2013) 0.85
A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. MAbs (2014) 0.84
The making of bispecific antibodies. MAbs (2017) 0.84
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing. Protein Eng Des Sel (2012) 0.83
Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. Proc Natl Acad Sci U S A (2014) 0.82
Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs (2015) 0.81
HIV antibodies for treatment of HIV infection. Immunol Rev (2017) 0.80
Advances in Antibody Design. Annu Rev Biomed Eng (2015) 0.80
Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. MAbs (2015) 0.79
Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. MAbs (2016) 0.78
Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery. Immunol Rev (2016) 0.78
A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets. J Biol Chem (2016) 0.77
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. Int J Mol Sci (2016) 0.77
Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties. MAbs (2016) 0.76
Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system. MAbs (2015) 0.76
Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study. Oncotarget (2017) 0.75
Mix and match: building manifold binding sites. Nat Biotechnol (1997) 0.75
Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments. MAbs (2016) 0.75
'In-Format' screening of a novel bispecific antibody format reveals significant potency improvements relative to unformatted molecules. MAbs (2016) 0.75
Targeted FcγR mediated clearance by a biparatopic bispecific antibody. J Biol Chem (2017) 0.75
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep (2017) 0.75
Multi-mechanistic monoclonal antibodies targeting S. aureus α-toxin and clumping factor A: Activity and efficacy comparisons of a mAb combination and an engineered bispecific antibody approach. Antimicrob Agents Chemother (2017) 0.75
A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6. PLoS One (2017) 0.75
Computational Design of a Specific Heavy Chain/κ Light Chain Interface for Expressing Fully IgG Bispecific Antibodies. Protein Sci (2017) 0.75
A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene. Cell (1983) 18.86
Detection of specific hybridoma clones by replica immunoadsorption of their secreted antibodies. Proc Natl Acad Sci U S A (1979) 13.60
Natural history of acute coronary heart attacks. A community study. Br Heart J (1972) 8.55
Immunoglobulin gene expression in transformed lymphoid cells. Proc Natl Acad Sci U S A (1983) 5.18
Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A (1984) 3.32
Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol (1989) 2.42
Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J (1988) 2.40
Natural history of unstable angina. Lancet (1972) 2.03
A quantitative difference in the immune response between male and female mice. Proc Soc Exp Biol Med (1968) 1.90
The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med (1991) 1.88
Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry (1995) 1.87
Polypeptide products of nonsense mutations. I. Termination fragments from nonsense mutations in the Z gene of the lac operon of Escherichia coli. J Mol Biol (1970) 1.84
Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods (1992) 1.74
Heavy chain-producing variants of a mouse myeloma cell line. J Immunol (1975) 1.73
Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med (1993) 1.73
Prognosis of new and worsening angina pectoris. Br Med J (1976) 1.59
Murine heavy chain disease. Eur J Immunol (1978) 1.50
A comparison of apparent mRNA half-life using kinetic labeling techniques vs decay following administration of transcriptional inhibitors. Anal Biochem (1991) 1.40
Estimation of antibodies specific for dextran. J Immunol (1978) 1.38
Production and properties of chimeric antibody molecules. Methods Enzymol (1989) 1.35
Membrane IgM, IgD, and IgG act as signal transmission molecules in a series of B lymphomas. J Immunol (1986) 1.34
Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol (1997) 1.32
Characterization of the J chain from polymeric immunoglobulins (IgA-IgM-immunological specificity-primary structure). Proc Natl Acad Sci U S A (1972) 1.31
Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res (2000) 1.31
Regulation of immunoglobulin expression in mouse myeloma cells. Cold Spring Harb Symp Quant Biol (1977) 1.28
Different VL and VH germ-line genes are used to produce similar combining sites with specificity for alpha(1----6)dextrans. J Immunol (1987) 1.27
Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci U S A (1990) 1.26
Myeloma mutant with a novel 3' flanking region: loss of normal sequence and insertion of repetitive elements leads to decreased transcription but normal processing of the alpha heavy-chain gene products. Mol Cell Biol (1986) 1.21
Transfectomas provide novel chimeric antibodies. Science (1985) 1.20
Policy for early discharge after acute myocardial infarction. Br Med J (1980) 1.19
Bone-marrow suppression associated with cimetidine. Ann Intern Med (1979) 1.17
Sequentially derived mutants of the constant region of the heavy chain of murine immunoglobulins. J Immunol (1979) 1.16
Sequences near the 3' secretion-specific polyadenylation site influence levels of secretion-specific and membrane-specific IgG2b mRNA in myeloma cells. Mol Cell Biol (1986) 1.16
Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med (1994) 1.16
Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol (1998) 1.15
Transfer and expression of immunoglobulin genes. Annu Rev Immunol (1984) 1.15
Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc Natl Acad Sci U S A (1987) 1.15
Characterization of the interaction between the herpes simplex virus type I Fc receptor and immunoglobulin G. J Biol Chem (1999) 1.14
Two alpha heavy chain disease proteins with different genomic deletions demonstrate that nonexpressed alpha heavy chain genes contain methylated bases. Proc Natl Acad Sci U S A (1981) 1.13
Immunochemical characterization of binding sites of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran. Mol Immunol (1982) 1.12
The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med (1991) 1.12
Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. EMBO J (1991) 1.09
Loss of a consensus splice signal in a mutant immunoglobulin gene eliminates the CH1 domain exon from the mRNA. Mol Cell Biol (1984) 1.09
Ultraviolet-Stimulated KHCO(3) Efflux from Rose Cells: Regulation of Cytoplasmic pH. Plant Physiol (1983) 1.09
The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (Ig)A1 and IgA2 isotypes. J Exp Med (2000) 1.06
Association constants of hybridoma antibodies specific for alpha (1 leads to 6) linked dextran determined by affinity electrophoresis. Mol Immunol (1982) 1.05
The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer (1994) 1.05
Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen. J Exp Med (1988) 1.03
Developmental regulation of membrane and secretory Ig gamma 2b mRNA. J Immunol (1989) 1.01
Studies on mouse hybridomas secreting IgM or IgA antibodies to alpha(1 to 6)-linked dextran. Mol Immunol (1981) 1.01
The identification of mouse myeloma cells which have undergone mutations in immunoglobulin production. Soc Gen Physiol Ser (1974) 1.01
Mutational events in mouse myeloma cells. Crit Rev Immunol (1981) 0.99
Sequences of variable regions of hybridoma antibodies to alpha (1----6) dextran in BALB/c and C57BL/6 mice. J Immunol (1985) 0.98
Expression of a VHC kappa chimaeric protein in mouse myeloma cells. Nature (1984) 0.98
Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci U S A (1995) 0.98
Somatically generated mouse myeloma variants synthesizing IgA half-molecules. J Exp Med (1981) 0.97
Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3. Proc Natl Acad Sci U S A (1992) 0.97
Production of secretory immunoglobulin A by a single mammalian cell. Proc Natl Acad Sci U S A (1997) 0.96
Targeting of functional antibody-CD59 fusion proteins to a cell surface. J Clin Invest (1999) 0.96
Mapping studies reveal unique epitopes on IgG recognized by rheumatoid arthritis-derived monoclonal rheumatoid factors. J Immunol (1993) 0.96
Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies. J Immunol Methods (1993) 0.95
In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice. Lab Anim Sci (1999) 0.95
Appearance of an early "primed state" in mice following the concomitant injections of antigen and specific antiserum. J Immunol (1972) 0.95
A common sequence motif near nonhomologous recombination breakpoints involving Ig sequences. J Immunol (1993) 0.93
Divergence of human alpha-chain constant region gene sequences. A novel recombinant alpha 2 gene. J Immunol (1994) 0.93
A variant of the dextran-binding mouse plasmacytoma J558 with altered glycosylation of its heavy chain and decreased reactivity with polymeric dextran. Biochemistry (1981) 0.93
Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. Cancer Res (1998) 0.93
Elimination of N-linked glycosylation sites from the human IgA1 constant region: effects on structure and function. J Immunol (1997) 0.93
Formation of hybridoma clones in soft agarose: effect of pH and of medium. Somatic Cell Genet (1980) 0.93
Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization. Mol Immunol (1994) 0.92
Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. J Immunol (2000) 0.92
Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1-->6) dextran antibody. J Immunol (1999) 0.92
Structural requirements for polymeric immunoglobulin assembly and association with J chain. J Biol Chem (1999) 0.91
Alternative splicing patterns in an aberrantly rearranged immunoglobulin kappa-light-chain gene. Proc Natl Acad Sci U S A (1985) 0.91
Chimeric antibodies with 17-1A-derived variable and human constant regions. Hybridoma (1986) 0.91
Residues critical for H-L disulfide bond formation in human IgA1 and IgA2. J Immunol (1996) 0.91
Molecular cloning of a human monoclonal antibody reactive to ganglioside GM3 antigen on human cancers. Cancer Res (1993) 0.89
Identification and characterization of a myristylated and palmitylated serine/threonine protein kinase. Biochem Biophys Res Commun (1999) 0.87
Site-specific and directional gene replacement mediated by Cre recombinase. J Immunol Methods (2000) 0.87
Functional and pharmacokinetic properties of antibody-avidin fusion proteins. J Immunol (1997) 0.86
Recombinant polymeric IgG: an approach to engineering more potent antibodies. Biotechnology (N Y) (1994) 0.85
Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface. J Biol Chem (2001) 0.85
Polypeptide products of nonsense mutations. II. Minor fragments produced by nonsense mutations in the z gene of the lactose operon of Escherichia coli. J Mol Biol (1971) 0.85
Repair of postcatheterization femoral pseudoaneurysms by color flow ultrasound guided compression. Am Heart J (1992) 0.85
Heavy-chain mutants derived from gamma 2b mouse myeloma: characterization of heavy-chain messenger ribonucleic acid, proteins, and secretion in delection mutants and messenger ribonucleic acid in gamma2a mutant progeny. Biochemistry (1981) 0.85
Psychological, topographic EEG, and CT scan correlates of frontal lobe function in schizophrenia. Psychiatry Res (1989) 0.84
Antibody-cytokine fusion proteins: innovative weapons in the war against cancer. Clin Exp Med (2004) 0.84
An analysis of heavy chain glycopeptides of hybridoma antibodies: correlation between antibody specificity and sialic acid content. J Immunol (1981) 0.84
ICR-191 and ethyl methanesulfonate induced mutagenesis at the immunoglobulin locus in the Y5606 cultured myeloma cell line. Mutat Res (1981) 0.83
Addition of a mu-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J Immunol (1995) 0.83
Genetically engineered antibodies: progress and prospects. Crit Rev Immunol (1992) 0.83
A colorimetric-enzymatic microassay for the quantitation of antibody-dependent complement activation. J Immunol Methods (1999) 0.83
Enhanced immunologic sensitization of mice by the simultaneous injection of antigen and specific antiserum. 3. The role of antigen in controlling the immune response elicited with immune complexes. J Immunol (1967) 0.83
Hybrid IgA2/IgG1 antibodies with tailor-made effector functions. Clin Immunol (2001) 0.82
The hinge as a spacer contributes to covalent assembly and is required for function of IgG. J Immunol (1997) 0.82
A mouse myeloma variant with a defect in light chain synthesis. Eur J Immunol (1979) 0.82